Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
-
Press release
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-… -
Press release
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with… -
Press release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands… -
Story Discovery
Breaking ground in Global Health
Manju Ujjini, Head of Lead Discovery for our Global Health Biomedical Research group, discusses what’s next for his team in drug discovery
-
Press release
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI… -
Press release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut… -
Press release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was well-… -
Press release
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple… -
Story
Victor Bulto and Thierry Diagana named to 2026 TIME100 Health List
Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.
-
Story Discovery
What's next in Neuroscience drug discovery
A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.
-
Press release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,… -
Ad hoc release
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from…
-
Press release
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-… -
Press release
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with… -
Press release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands… -
Press release
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI… -
Press release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut… -
Press release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was well-… -
Press release
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple… -
Press release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,… -
Ad hoc release
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from… -
Ad hoc release
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +8% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +14% (kWk, +12% USD)Das Umsatzwachstum beruhte auf… -
Press release
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development and review of treatments for serious… -
Press release
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT…
-
Ad hoc release
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from… -
Ad hoc release
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +8% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +14% (kWk, +12% USD)Das Umsatzwachstum beruhte auf… -
Ad hoc release
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III… -
Ad hoc release
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for… -
Ad hoc release
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority… -
Ad hoc release
Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +7% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +7% (kWk, +6% USD)Das Umsatzwachstum beruhte… -
Ad hoc release
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the… -
Ad hoc release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled… -
Ad hoc release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s… -
Ad hoc release
Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March… -
Ad hoc release
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +12% USD) with core operating income1 up +21% (cc, +20% USD) Sales growth driven by continued strong performance from Kisqali (+… -
Ad hoc release
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™…
-
Statement
Bringing breakthroughs to more patients
-
Statement
Vas Narasimhan named to 2025 TIME100 Health list
-
Statement
Europe talks health sovereignty — now it must deliver
-
Statement
Novartis statement on Maximum Fair Price for Entresto
-
Statement
Violence against innocent people runs counter to our work to improve human health
-
Statement
Novartis condemns the terrorist actions against people in Israel and loss of innocent lives
-
Statement
Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
Statement
Novartis provides support for Moroccan earthquake victims
-
Statement
GT005 (PPY988): Development Program in Geographic Atrophy
-
Statement
Novartis statement on filing of Inflation Reduction Act lawsuit
-
Statement
Novartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program
-
Statement
European Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo® (crizanlizumab)
-
Story Discovery
Breaking ground in Global Health
Manju Ujjini, Head of Lead Discovery for our Global Health Biomedical Research group, discusses what’s next for his team in drug discovery
-
Story
Victor Bulto and Thierry Diagana named to 2026 TIME100 Health List
Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.
-
Story Discovery
What's next in Neuroscience drug discovery
A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.
-
Story Access to Healthcare Infectious Diseases
How Novartis is helping to eliminate leprosy
Leprosy is one of the world’s oldest infectious diseases – yet there are still around 200,000 cases every year1. As the only supplier of multidrug therapy, in January 2026 Novartis renewed its partnership to provide the medicine via the WHO, protecting vital access to treatment.
-
Story Access to Healthcare
Why advocating for your MS is so important
-
Story People and Culture
Science in Motion: Autumn and Sabrina's Noteworthy Novartis Adventure
In the ever-evolving world of STEM, where innovation and discovery are to the forefront, the stories of women who have made their mark are both inspiring and essential. Today, we're shining a spotlight on two dedicated Novartis employees who have chosen to begin their careers in manufacturing operations, paving the way for others to follow.
-
Story Patient Perspectives
Marc’s story: Raising awareness of elevated Lp(a) in cardiovascular disease
-
Story People and Culture
Parental leave – A leadership opportunity
At Novartis, we believe in the importance of balancing professional and personal responsibilities. This belief is embodied through our inclusive parental leave policy, which supports all our people in taking the time they need to be with their families during significant life events. To understand how this truly supports our colleagues we invited Sumeet, Global Head of Service Enablement & Governance, People Services & Solutions to share his story with us. -
Story People and Culture
Biologist to Head-hunter
I sometimes overlook what I’ve achieved or overcome to arrive at this point in my career. The opportunities I’ve embraced, the advice I’ve received and the heartfelt decisions I’ve made. So sharing my journey with you was an opportunity to pause and reflect, strengthening my belief that change is not always easy, but it can be very rewarding.
-
Story Discovery
Addressing unmet needs for inherited neuromuscular diseases
Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.
-
Story Access to Healthcare
Negative impact of the IRA on patient access to innovative treatments
At Novartis, we are constantly pushing the limits of science to develop and deliver transformative medicines that fight disease and help people live life on their terms.
-
Story People and Culture
Every number has a story – my journey to Novartis as a Refugee
The current refugee crisis is one of the world's greatest humanitarian challenges. Svitlana shares her story of her journey to Novartis and how her work as part of the Giving and Volunteering team is opening the doors to refugees and other marginalized groups and allowing our people to make a difference by helping those who are most vulnerable.
Stories
Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.
Events
Keep informed about the latest Novartis events. From upcoming congresses and conferences to special forums, explore our event calendar for ongoing opportunities to connect and engage.
